COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation
The novel coronavirus infection (COVID-19) is caused by the new coronavirus SARS-CoV-2 and is characterized by an exaggerated inflammatory response that can lead to severe manifestations such as adult respiratory syndrome, sepsis, coagulopathy, and death in a proportion of patients. Among other fact...
Main Authors: | Wolfgang Miesbach MD, Michael Makris MD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-07-01
|
Series: | Clinical and Applied Thrombosis/Hemostasis |
Online Access: | https://doi.org/10.1177/1076029620938149 |
Similar Items
-
COVID-19-Associated Coagulopathy: A Case Report of Thrombosis despite Therapeutic Anticoagulation
by: Habiba Hussain, et al.
Published: (2020-01-01) -
Thrombosis and coagulopathy in COVID‐19: An illustrated review
by: Marcel Levi, et al.
Published: (2020-07-01) -
The Challenging Anticoagulant Therapy in COVID19 Patient with Associated Coagulopathy
by: Raissa Virgy Rianda, et al.
Published: (2021-07-01) -
COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response
by: Apoorva Jayarangaiah MD, et al.
Published: (2020-07-01) -
Coagulopathy and COVID-19
by: Onur Yazici, et al.
Published: (2020-01-01)